Salama, A. K. S., Cheshuk, V., Siveke, J., Berrocal, A., Abdullah, S. E., Lockwood, S., … Kee, D. (2021). 1014P Characterization of cytokine release syndrome (CRS) following treatment with tebentafusp in previously untreated patients with metastatic uveal melanoma. In Annals of Oncology (Vol. 32, pp. S855–S855). Elsevier BV. https://doi.org/10.1016/j.annonc.2021.08.1398

Salama, A. K. S., V. Cheshuk, J. Siveke, A. Berrocal, S. E. Abdullah, S. Lockwood, M. L. McCully, and D. Kee. “1014P Characterization of cytokine release syndrome (CRS) following treatment with tebentafusp in previously untreated patients with metastatic uveal melanoma.” In Annals of Oncology, 32:S855–S855. Elsevier BV, 2021. https://doi.org/10.1016/j.annonc.2021.08.1398.

Salama AKS, Cheshuk V, Siveke J, Berrocal A, Abdullah SE, Lockwood S, et al. 1014P Characterization of cytokine release syndrome (CRS) following treatment with tebentafusp in previously untreated patients with metastatic uveal melanoma. In: Annals of Oncology. Elsevier BV; 2021. p. S855–S855.

Salama, A. K. S., et al. “1014P Characterization of cytokine release syndrome (CRS) following treatment with tebentafusp in previously untreated patients with metastatic uveal melanoma.” Annals of Oncology, vol. 32, Elsevier BV, 2021, pp. S855–S855. Crossref, doi:10.1016/j.annonc.2021.08.1398.

Salama AKS, Cheshuk V, Siveke J, Berrocal A, Abdullah SE, Lockwood S, McCully ML, Kee D. 1014P Characterization of cytokine release syndrome (CRS) following treatment with tebentafusp in previously untreated patients with metastatic uveal melanoma. Annals of Oncology. Elsevier BV; 2021. p. S855–S855.